<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Basic transcription factor 3 (BTF3) is a general <z:chebi fb="40" ids="33697">RNA</z:chebi> polymerase II transcription factor and is also involved in <z:mpath ids='MPATH_3'>apoptosis</z:mpath> regulation </plain></SENT>
<SENT sid="1" pm="."><plain>Increasing evidence shows that BTF3 is aberrantly expressed in several kinds of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, but there is no study to analyze BTF3 expression in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) patients </plain></SENT>
<SENT sid="2" pm="."><plain>Applying immunohistochemistry, we detected BTF3 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> (n = 156), the corresponding distant (n = 42), adjacent <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa (n = 96), <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> (n = 35), and analyzed its relationships with clinicopathological and biological variables </plain></SENT>
<SENT sid="3" pm="."><plain>Our results showed that BTF3 staining significantly increased from distant or adjacent <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa to primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> (p &lt; 0.0001) or <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> (p = 0.002 and p &lt; 0.0001) </plain></SENT>
<SENT sid="4" pm="."><plain>BTF3 was higher in distal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> than in proximal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (57 % vs. 39 %, p = 0.041) </plain></SENT>
<SENT sid="5" pm="."><plain>It also showed stronger staining in primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> stage I and II than that in stage III and IV (64 % vs. 35 %, p = 0.0004), or <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> (64 % vs. 29 %, p = 0.004) </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancers</z:e> with better differentiation had a higher expression than those with worse differentiation (56 % vs. 37 %, p = 0.031) </plain></SENT>
<SENT sid="7" pm="."><plain>There were positive correlations of BTF3 expression with nuclear factor kappa B (NF-κB), RAD50, MRE11, NBS1, and AEG-1 (p &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, BTF3 overexpression may be an early event in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> development and could be useful biomarker for the early stage of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>BTF3 has positive correlations with NF-κB, RAD50, MRE11, NBS1 and AEG-1, and might influence complex signal pathways in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>